Overall Survival Analysis From KYPROLIS ® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology

KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Compared to Velcade® (bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients KYPROLIS is the First and Only Multiple Myeloma Therapy Proven to Extend Overall Survival in a Head-to-Head Comparison With a Current Standard of Care in the Relapsed Setting THOUSAND OAKS, Calif., Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published online first in The Lancet Oncology. Data showed that KYPROLIS® (carfilzomib) administered at 56 mg/m2 twice weekly and dexamethasone (Kd56) reduced...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news